ACE and type 2 diabetes mellitus: • Age ≥18 years at the time of signing informed consent• Diagnosed with T2D ≥180 days prior to the day of screening• HbA1c ≤9.0% (≤75 mmol/mol)• RAS inhibitor use in the form of ACE inhibition or an ARB (treatment dose stable for 28 days)• For participants not in the biopsy subgroup: serum creatinine–based eGFR ≥30–≤75 ml/min/1.73 m2a,b• UACR ≥20–<5000 mg/g